Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

Not Applicable

• Conditions: Infertility
• Interventions: Drug: Ovitrelle

• Registration Number: NCT01205009
• Lead Sponsor: Hadassah Medical Organization

Brief Summary

In an era of delayed fertility plans, there is increasing need for fertility treatment in older women with poor response. Human chorionic gonadotropin (hCG) supplementation prior to treatment, as a thecal stimulant, may improve folliculogenesis and ovarian response.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-08-30
• Status Verified: 2010-09
• Study First Submitted QC: 2010-09-16
• Study First Posted: 2010-09-20
• Last Update Submitted: 2011-03-01
• Last Update Posted: 2011-03-02
• Study Start: 2011-04
• Primary Completion: 2012-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

• women >39 years on IVF treatment

Exclusion Criteria

• polycystic ovary syndrome
• Any allergy to injection of human chorionic gonadotropin before

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ovitrelle supplemantation	Ovitrelle	The women will be given 250 mcg of Ovitrelle prior to their IVF cycle

Primary Outcome Measures

Name	Time	Method
number of oocytes retrieved	1 month

Trial Locations

Locations (1)

Hadassah Medical Center; 🇮🇱 Jerusalem, Israel